CUMULUS NEUROSCIENCE LIMITED

• ◆

  Material uncertainty over going concern

  The Group is currently loss-making and in a net liability position. The Group expects to report further losses for the year ending 31 December 2026. In April 2025, the Group received a significant investment in the form of convertible loan notes, which are due to mature in April 2027. Letters of support have been obtained from the investors, which include confirmation that they do not intend to request repayment of the convertible loan notes within the next 12 months.

• ·

  Going-concern uncertainty disclosed

• ·

  Negative shareholders' funds

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. Year-on-year comparison hidden: this filing's period length differs materially from the prior year. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. CUMULUS NEUROSCIENCE LIMITED 2020-12-17 → present
2. BRAINWAVEBANK LTD. 2015-01-05 → 2020-12-17

Accounting basis

FRS 102 §1A

Reporting scope

Consolidated group

Auditor

AAB Group Accountants Limited

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Group is currently loss-making and in a net liability position. The Group expects to report further losses for the year ending 31 December 2026. In April 2025, the Group received a significant investment in the form of convertible loan notes, which are due to mature in April 2027. Letters of support have been obtained from the investors, which include confirmation that they do not intend to request repayment of the convertible loan notes within the next 12 months.”

Group structure

1. CUMULUS NEUROSCIENCE LIMITED · parent
   1. Cumulus Neuroscience Inc 100% · USA

Significant events

• “In December 2024, the Company entered into bridging loan agreements totalling £60,000. The loans accrued interest at 8% per annum and had a maturity of 3 months. They were fully settled in May 2025.”
• “During the year, the Company entered into convertible loan agreements, the principal amount was £3,760,000. The loans accrue interest at 15% per annum and have a maturity of 2 years from the date of the agreement.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

11

last 12 months

Capital events

5

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.